Naphazoline: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026🚩 Report this page

Naphazoline

Active ingredient · 3 therapeutic classes

Sold as MURINE IRRITATION &…

GB MHRA

Drug class: Sympathomimetics, Plain
Availability: See label
Markets covered: 1
Products on record: 3

R01AASympathomimetics, Plain R01ABSympathomimetics, Combinations Excl. Corticosteroids S01GASympathomimetics Used As Decongestants

Overview

Naphazoline is an active pharmaceutical ingredient in the Sympathomimetics, Plain group (R01AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	3	May 29, 2026

GBUnited Kingdom· MHRA

3 products

Uses

GBOfficial regulatory label· revised March 20, 2026[1]

For the relief of occasional, minor redness and irritation of the eye. Murine is indicated in adults and children aged 12 years and over.

How to take

Drug interactions

Known interactions involving Naphazoline. Select one for details. This list is informational and not a complete interaction checker.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL182590009 · revised March 20, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised March 20, 2026[1]

Adverse events which have been associated with naphazoline hydrochloride are given below, tabulated by system organ class and frequency.
Frequencies are defined as:
Very common (≥1/10); Common Page 4 of 7 (≥1/100 to <1/10); Uncommon (≥1/1000 to <1/100); Rare (≥1/10,000 to <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.
Very occasionally transient eye irritation (including stinging and itching), transient blurred vision, and mydriasis (pupil dilation) have been reported. System Organ Class Frequency Adverse Events Immune System Disorders Not known Hypersensitivity Nervous System Disorders Not known Headache, dizziness Eye Disorders Not known Blurred vision, pupil dilation, eye irritation, eye pain, ocular hyperaemia1 Gastrointestinal Disorders Not known Nausea Description of Selected Adverse Reactions 1Following long term use a rebound secondary hyperaemia may occur.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised March 20, 2026[1]

This product is for intermittent or occasional use only. Rebound effects have been reported after prolonged and/or excessive use of naphazoline containing eye drops. Patients who are being treated for high blood pressure, depression, heart disease, arteriosclerosis, diabetes or increased thyroid activity, should consult their doctor before using the drops as naphazoline may exacerbate vasoconstriction.
9). Murine should not be used if there is an eye condition characterised by continued redness, pain or blurring of vision. If there is any eye pain, vision changes, photophobia, continued redness or irritation of the eye, or if after 24 hours the condition worsens or shows no sign of improvement, discontinue use and consult a doctor.
Patients who have had eye surgery should not take Murine until they have been advised by a doctor that their recovery is complete. Use of naphazoline in the eye may liberate pigment granules from the iris, especially when given in high doses to elderly patients.
, desflurane, sevoflurane). Murine should not to be used in children younger than 12 years of age. Contains benzalkonium chloride which may cause eye irritation and is known to discolour soft contact lenses. Avoid contact with soft contact lenses; remove contact lenses prior to application and wait at least 15 minutes before re-insertion.
Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised.
Page 3 of 7 If the solution changes colour or becomes cloudy do not use.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations